Authors: Jonsson, E Friberg, LE Karlsson, MO Hassan, SB Nygren, P Kristensen, J Tholander, B Binderup, L Larsson, R

Citation: E. Jonsson et al., In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients, CANCER LETT, 162(2), 2001, pp. 193-200

Authors: von Heideman, A Sandstrom, M Csoka, K Tholander, B Larsson, R Bergh, J Nygren, P

Citation: A. Von Heideman et al., Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients, ANN ONCOL, 11(10), 2000, pp. 1301-1307

Authors: Ericsson, H Tholander, B Regardh, CG

Citation: H. Ericsson et al., In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animalspecies and man, EUR J PH SC, 8(1), 1999, pp. 29-37

Authors: Ericsson, H Tholander, B Bjorkman, JA Nordlander, M Regardh, CG

Citation: H. Ericsson et al., Pharmacokinetics of new calcium channel antagonist clevidipine in the rat,rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs, DRUG META D, 27(5), 1999, pp. 558-564

Authors: Trope, C Hogberg, T Kaern, J Bertelsen, K Bjorkholm, E Boman, K Himmelmann, A Horvath, G Jacobsen, A Kuoppola, T Vartianen, J Lund, B Onsrud, M Puistola, U Salmi, T Scheistroen, M Sandvei, R Simonsen, E Sorbe, B Tholander, B Westberg, R

Citation: C. Trope et al., Long-term results from a phase II study of single agent paclitaxel (Taxol (R)) in previously platinum treated patients with advanced ovarian cancer: The Nordic experience, ANN ONCOL, 9(12), 1998, pp. 1301-1307